Jiangsu T-Win Biopharmaceutical

Jiangsu T-Win Biopharmaceutical is a Chinese biotechnology company and a key subsidiary of Guangdong Teenk Pharmaceutical. The company specializes in the development and manufacturing of high-end biological drugs, with a primary focus on monoclonal antibody biosimilars. Its lead pipeline candidates include biosimilars for Bevacizumab (CK-0801) and Cetuximab (CK-0803), targeting various cancers such as colorectal and lung cancer. Based in Suzhou, the company maintains a large-scale R&D and production facility designed to meet international GMP standards. Jiangsu T-Win plays a central role in its parent company's strategy to expand from pharmaceutical distribution into innovative drug development.